<DOC>
	<DOCNO>NCT01412034</DOCNO>
	<brief_summary>The available medication use treat HoFH target reduce circulating level total LDL-cholesterol . These measure retard progression cardiovascular disease , however , unlikely regress exist disease due year cholesterol accumulation vessel wall therefore adequately reduce exist risk ischemic event . HDL multiple action could lead plaque stabilization regression , rapid removal large quantity cholesterol vasculature , improvement endothelial function , protection oxidative damage reduction inflammation . This study assess effect CER-001 , recombinant human Apo-A-1 base HDL mimetic , index atherosclerotic plaque progression regression assess 3Tesla MRI measurement patient HoFH .</brief_summary>
	<brief_title>Effect CER-001 Plaque Volume Homozygous Familial Hypercholesterolemia ( HoFH ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Male female subject 12 year old Subject present Homozygous FH Weight &gt; 100 kg Subjects significant health problem recent past include blood disorder , cancer , digestive problem Female subject childbearing potential Known major hematologic , renal , hepatic , metabolic , gastrointestinal endocrine dysfunction Contraindication MRI scan would preclude use contrastenhanced 3TMRI</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Homozygous Familial Hypercholesterolemia</keyword>
	<keyword>Familial Hypercholesterolemia</keyword>
	<keyword>HDL mimetic</keyword>
	<keyword>ApoA-1</keyword>
</DOC>